Personalized Intervention Based on Early Detection of Atherosclerosis

Journal of the American College of Cardiology, Год журнала: 2024, Номер 83(21), С. 2112 - 2127

Опубликована: Май 1, 2024

Язык: Английский

---

Antioxidant and Anti-Inflammatory Effects of Bioactive Compounds in Atherosclerosis

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(3), С. 1379 - 1379

Опубликована: Фев. 6, 2025

Atherosclerosis, a chronic inflammatory disease characterized by the accumulation of lipids and immune cells within arterial walls, remains leading cause cardiovascular morbidity mortality worldwide. Oxidative stress inflammation are central to its pathogenesis, driving endothelial dysfunction, foam cell formation, plaque instability. Emerging evidence highlights potential bioactive compounds with antioxidant anti-inflammatory properties mitigate these processes promote vascular health. This review explores mechanisms through which compounds-such as polyphenols, carotenoids, flavonoids, omega-3 fatty acids, coenzyme Q10, other natural compounds-modulate oxidative in atherosclerosis. It examines their effects on key molecular pathways, including inhibition reactive oxygen species (ROS) production, suppression nuclear factor-κB (NF-κB), modulation cytokines. By integrating current knowledge, this underscores therapeutic dietary supplemental complementary strategies for managing atherosclerosis, paving way future research clinical applications.

Язык: Английский

---

Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial

Journal of clinical lipidology, Год журнала: 2023, Номер 17(4), С. 491 - 503

Опубликована: Июнь 3, 2023

Obicetrapib, a selective cholesteryl ester transfer protein (CETP) inhibitor, reduces low-density lipoprotein cholesterol (LDL-C), non-high-density (non-HDL-C), particles, and apolipoproteins, when added to high-intensity statin in patients with dyslipidemia.To evaluate the safety lipid-altering efficacy of obicetrapib plus ezetimibe combination therapy as an adjunct therapy.This double-blind, randomized, phase 2 trial administered 10 mg (n = 40), 39), or placebo 40) for 12 weeks LDL-C >70 mg/dL triglycerides (TG) <400 mg/dL, on stable statin. Endpoints included concentrations lipids, proprotein convertase subtilisin kexin type 9 (PCSK9), safety, tolerability.Ninety-seven were primary analysis (mean age 62.6 years, 63.9% male, 84.5% white, average body mass index 30.9 kg/m2). decreased from baseline week by 63.4%, 43.5%, 6.35% combination, monotherapy, groups, respectively (p<0.0001 vs. placebo). levels <100, <70, <55 achieved 100%, 93.5%, 87.1%, respectively, taking combination. Both active treatments also significantly reduced non-HDL-C, apolipoprotein B, total small LDL particles. Obicetrapib was well tolerated no issues identified.The lowered atherogenic lipid parameters, safe top elevated LDL-C.

Язык: Английский

---

Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association

Arteriosclerosis Thrombosis and Vascular Biology, Год журнала: 2023, Номер 43(10)

Опубликована: Сен. 14, 2023

The objective of this scientific statement is to evaluate contemporary evidence that either supports or refutes the conclusion aggressive low-density lipoprotein cholesterol lowering lipid exerts toxic effects on brain, leading cognitive impairment dementia hemorrhagic stroke. writing group used literature reviews, references published clinical and epidemiology studies, public health guidelines, authoritative statements, expert opinion summarize existing identify gaps in current knowledge. Although some retrospective, case control, prospective longitudinal studies suggest statins are associated with dementia, preponderance observational data from randomized trials do not support conclusion. risk a stroke statin therapy patients without history cerebrovascular disease nonsignificant, achieving very low levels does increase risk. Data reflecting lipid-lowering treatment among robust require additional focused study.

Язык: Английский

---

Dioscin pretreatment ameliorates ferroptosis in cardiomyocytes after myocardial infarction via inhibiting endoplasmic reticulum stress

Molecular Medicine, Год журнала: 2025, Номер 31(1)

Опубликована: Янв. 29, 2025

Язык: Английский

---

Refining the impact of early intermittent hyperlipidemia on atherosclerosis: Unveiling the role of neutrophil reprogramming, sex differences, gut microbiota, and maternal hypercholesterolemia

The FASEB Journal, Год журнала: 2025, Номер 39(5)

Опубликована: Март 6, 2025

Atherosclerotic cardiovascular diseases (ASCVDs) remain a leading cause of mortality, with early cholesterol control being pivotal in mitigating long-term risk. Recent findings suggest that intermittent hyperlipidemia, characterized by oscillatory exposure, uniquely accelerates atherosclerosis compared to continuous high-fat diets. This review synthesizes emerging evidence on hyperlipidemia's impact atherogenesis, emphasizing macrophage dysfunction, autophagy impairment, and efferocytosis deficits. We also discuss critical gaps, including sex-specific differences, gut-microbiota interactions, the influence maternal hypercholesterolemia. Notably, recent insights into IL-1β-dependent neutrophil reprogramming under diets reveal novel inflammatory mechanisms driving plaque destabilization. Addressing these gaps will advance our understanding atherogenesis guide development innovative prevention strategies therapeutic interventions.

Язык: Английский

---

Nuts and Cardiovascular Disease Outcomes: A Review of the Evidence and Future Directions

Nutrients, Год журнала: 2023, Номер 15(4), С. 911 - 911

Опубликована: Фев. 11, 2023

Nuts are nutrient-rich foods that contain many bioactive compounds beneficial for cardiovascular health. Higher consumption of nuts has been associated with a reduced risk several diseases (CVD) in prospective cohort studies, including 19% and 25% lower CVD incidence mortality, respectively, 24% 27% coronary heart disease respectively. An 18% stroke 15% atrial fibrillation, total mortality have also observed. The role incidence, subtypes, peripheral arterial failure less consistent. This narrative review summarizes recommendations by clinical practice guidelines governmental organizations, epidemiological evidence outcomes, nut-containing dietary patterns, potential mechanisms reduction, future research directions, such as the use biomarkers to help better assess nut intake. Although there still some uncertainties around prevention which require further research, summarized this review, is substantial amount supports consuming will positive impact on primary secondary CVD.

Язык: Английский

---

Eliminating atherosclerotic cardiovascular disease residual risk

European Heart Journal, Год журнала: 2023, Номер 44(45), С. 4731 - 4733

Опубликована: Июль 14, 2023

Язык: Английский

---

A Non-Coronary, Peripheral Arterial Atherosclerotic Disease (Carotid, Renal, Lower Limb) in Elderly Patients—A Review PART II—Pharmacological Approach for Management of Elderly Patients with Peripheral Atherosclerotic Lesions outside Coronary Territory

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(5), С. 1508 - 1508

Опубликована: Март 5, 2024

Background: Aging is a key risk factor for atherosclerosis progression that associated with increased incidence of ischemic events in supplied organs, including stroke, coronary events, limb ischemia, or renal failure. Cardiovascular disease the leading cause death and major disability adults ≥ 75 years age. Atherosclerotic occlusive affects everyday activity, quality life, it reduced life expectancy. As most multicenter randomized trials exclude elderly very patients, particularly those severe comorbidities, physical cognitive dysfunctions, frailty, residence nursing home, there insufficient data on management older patients presenting atherosclerotic lesions outside territory. This results serious critical gaps knowledge lack guidance appropriate medical treatment. In addition, due to variety comorbidities elderly, average daily number pills taken by octogenarians exceeds nine. Polypharmacy frequently drug therapy problems related interactions, toxicity, falls injury, delirium, non-adherence. Therefore, we have attempted gather treatment extra-cardiac indicating where some evidence are evidence-based medicine. Public PubMed databases were searched review existing effectiveness lipid-lowering, antithrombotic, new glucose-lowering medications disease.

Язык: Английский

---

Discovery of ASGR1 and HMGCR dual-target inhibitors based on supervised learning, molecular docking, molecular dynamic simulations, and biological evaluation

Bioorganic Chemistry, Год журнала: 2025, Номер 158, С. 108326 - 108326

Опубликована: Март 3, 2025

Язык: Английский

---